In-depth analysis of Pfizer's stock performance: $PFE. As Pfizer's stock hits a 52-week low, we explore its income statement and CEO's vision for cancer drugs as the next big leap. Discover the latest trends and potential opportunities in Pfizer's financial health and future growth prospects.